All In Biotech

Drug Trial Radar · NCT01416181

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Participants With Secondary Progressive Multiple Sclerosis

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With Secondary Progressive Multiple Sclerosis, With Optional Open-Label Extension

Last checked: Nov 20, 2026Latest source record: Sep 11, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registryPivotal-lookingPhase 3. Randomized with 889 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

889

Actual

Start

Sep 13, 2011

Primary completion

Jul 28, 2015

Study completion Apr 13, 2016

Sponsor

Lead sponsor
BiogenBiogen (BIIB)
Sponsor type
Industry
First posted
Aug 12, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 58 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 3b, multicenter, international study conducted in 2 parts. Upon completion of the placebo-controlled period (Part 1), participants will have the option of enrolling in a 2-year open-label extension (Part 2). Part 1: The primary objective of the study is to investigate whether treatment with natalizumab slows the accumulation of disability not related to relapses in participants with secondary progressive multiple sclerosis (SPMS). The secondary objectives of Part 1 of this study are to determine the proportion of participants with consistent improvement in Timed 25-Foot Walk (T25FW), the change in participant-reported ambulatory status as measured by the 12-item MS Walking Scale (MSWS-12), the change in manual ability based on the ABILHAND Questionnaire, the impact of natalizumab on participant-reported quality of life using the Multiple Sclerosis Impact Scale-29 Physical (MSIS-29 Physical), the change in whole brain volume between the end of study and Week 24 using magnetic resonance imaging (MRI) and the proportion of participants experiencing progression of disability as measured by individual physical Expanded Disability Status Scale (EDSS) system scores. Part 2: The primary objective of Part 2 of the study is to evaluate the safety profile of natalizumab in participants with SPMS. The secondary objectives of Part 2 of the study are to investigate long-term disability (based on clinical or participant-reported assessments) in participants with SPMS receiving natalizumab treatment for approximately 4 years and to assess change in brain volume and T2 lesion volume.

Conditions

  • Secondary Progressive Multiple Sclerosis

Interventions

  • natalizumabDrug

    Administered as specified in the treatment arm

  • PlaceboDrug

    Matched placebo in part 1

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part 1: Percentage of Participants With Confirmed Progression of Disability in One or More of the Expanded Disability Status Scale (EDSS), Timed 25-Foot Walk (T25FW), or 9-Hole Peg Test (9HPT)Time frame: Up to 96 weeks (2 years)
  2. Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)Time frame: 218 weeks

Locations

161 sites in 17 countries. Site status is shown where the registry gives one.

  • Research Site

    Phoenix, Arizona

  • Research Site

    Tucson, Arizona

  • Research Site

    Fullerton, California

  • Research Site

    Los Angeles, California

  • Research Site

    Aurora, Colorado

  • Research Site

    Tampa, Florida

  • Research Site

    Chicago, Illinois

  • Research Site

    Lake Barrington, Illinois

  • Research Site

    Peoria, Illinois

  • Research Site

    Indianapolis, Indiana

  • Research Site

    Indianapolis, Indiana

  • Research Site

    Kansas City, Kansas

  • Research Site

    Lexington, Kentucky

  • Research Site

    Lexington, Kentucky

  • Research Site

    Baltimore, Maryland

  • Research Site

    Burlington, Massachusetts

  • Research Site

    Omaha, Nebraska

  • Research Site

    Lebanon, New Hampshire

  • Research Site

    Teaneck, New Jersey

  • Research Site

    Latham, New York

  • Research Site

    New York, New York

  • Research Site

    Advance, North Carolina

  • Research Site

    Charlotte, North Carolina

  • Research Site

    Raleigh, North Carolina

  • Research Site

    Akron, Ohio

  • Research Site

    Uniontown, Ohio

  • Research Site

    Oklahoma City, Oklahoma

  • Research Site

    Clackamas, Oregon

  • Research Site

    Portland, Oregon

  • Research Site

    Portland, Oregon

  • Research Site

    Nashville, Tennessee

  • Research Site

    Charlottesville, Virginia

  • Research Site

    Seattle, Washington

  • Research Site

    Green Bay, Wisconsin

  • Research Site

    Milwaukee, Wisconsin

  • Research Site

    La Louvière, Belgium

  • Research Site

    Melsbroek, Belgium

  • Research Site

    Overpelt, Belgium

  • Research Site

    Calgary, Alberta, Canada

  • Research Site

    Edmonton, Alberta, Canada

Showing 40 of 161 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.